Wu Tian, Zeng Zheng, Yu Yanyan
Department of Infectious Diseases, Peking University First Hospital, Beijing 100034, China.
Microorganisms. 2024 May 17;12(5):1020. doi: 10.3390/microorganisms12051020.
Non-alcoholic fatty liver disease (NAFLD) is the most prevalent chronic liver condition worldwide. Numerous studies conducted recently have demonstrated a connection between the dysbiosis of the development of NAFLD and gut microbiota. Rebuilding a healthy gut ecology has been proposed as a strategy involving the use of probiotics. The purpose of this work is to investigate and compare the function of probiotics () and VSL#3 in NAFLD mice. Rodent NAFLD was modeled using a methionine choline-deficient diet (MCD) with/without oral probiotic delivery. Subsequently, qPCR, histological staining, and liver function tests were conducted. Mass spectrometry-based analysis and 16S rDNA gene sequencing were used to investigate the liver metabolome and gut microbiota. We found that while both and VSL#3 reduced hepatic fat content, outperformed VSL#3. Furthermore, probiotic treatment restored the β diversity of the gut flora and decreased the abundance of pathogenic bacteria such as . These probiotics altered the metabolism in MCD mice, especially the glycerophospholipid metabolism. In conclusion, our findings distinguished the role of and VSL#3 in NAFLD and indicated that oral-gavage probiotics remodel gut microbiota and improve metabolism, raising the possibility of using probiotics in the cure of NAFLD.
非酒精性脂肪性肝病（NAFLD）是全球最普遍的慢性肝脏疾病。最近进行的大量研究表明，NAFLD的发生发展与肠道微生物群失调之间存在关联。重建健康的肠道生态已被提议作为一种使用益生菌的策略。这项工作的目的是研究和比较益生菌（）和VSL#3在NAFLD小鼠中的作用。使用含/不含口服益生菌的蛋氨酸胆碱缺乏饮食（MCD）建立啮齿动物NAFLD模型。随后，进行了qPCR、组织学染色和肝功能测试。基于质谱的分析和16S rDNA基因测序用于研究肝脏代谢组和肠道微生物群。我们发现，虽然和VSL#3都降低了肝脏脂肪含量，但优于VSL#3。此外，益生菌治疗恢复了肠道菌群的β多样性，并且减少了诸如等病原菌的丰度。这些益生菌改变了MCD小鼠的代谢，尤其是甘油磷脂代谢。总之，我们的研究结果区分了和VSL#3在NAFLD中的作用，并表明口服灌胃益生菌可重塑肠道微生物群并改善代谢，增加了使用益生菌治疗NAFLD的可能性。
